Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Contribution of the uremic milieu to an increased pro-inflammatory monocytic phenotype in chronic kidney disease.

Borges Bonan N, Schepers E, Pecoits-Filho R, Dhondt A, Pletinck A, De Somer F, Vanholder R, Van Biesen W, Moreno-Amaral A, Glorieux G.

Sci Rep. 2019 Jul 15;9(1):10236. doi: 10.1038/s41598-019-46724-5.

2.

Identification and Evaluations of Novel Insecticidal Proteins from Plants of the Class Polypodiopsida for Crop Protection against Key Lepidopteran Pests.

Liu L, Schepers E, Lum A, Rice J, Yalpani N, Gerber R, Jiménez-Juárez N, Haile F, Pascual A, Barry J, Qi X, Kassa A, Heckert MJ, Xie W, Ding C, Oral J, Nguyen M, Le J, Procyk L, Diehn SH, Crane VC, Damude H, Pilcher C, Booth R, Liu L, Zhu G, Nowatzki TM, Nelson ME, Lu AL, Wu G.

Toxins (Basel). 2019 Jul 1;11(7). pii: E383. doi: 10.3390/toxins11070383.

3.

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients.

Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, Vanholder R, Brigant B, Pletinck A, Diouf M, Burtey S, Choukroun G, Massy ZA, Metzinger L; European Uremic Toxin Work Group-EUTox.

Sci Rep. 2019 Mar 14;9(1):4477. doi: 10.1038/s41598-019-41101-8.

4.

White noise speech illusions in the general population: The association with psychosis expression and risk factors for psychosis.

Schepers E, van Os J, Lousberg R.

PLoS One. 2019 Feb 20;14(2):e0211914. doi: 10.1371/journal.pone.0211914. eCollection 2019.

5.

Gut microbiota dynamics and uraemic toxins: one size does not fit all.

Joossens M, Faust K, Gryp T, Nguyen ATL, Wang J, Eloot S, Schepers E, Dhondt A, Pletinck A, Vieira-Silva S, Falony G, Vaneechoutte M, Vanholder R, Van Biesen W, Huys GRB, Raes J, Glorieux G.

Gut. 2018 Nov 21. pii: gutjnl-2018-317561. doi: 10.1136/gutjnl-2018-317561. [Epub ahead of print] No abstract available.

6.

Cardiovascular disease after transplantation: an emerging role of the immune system.

Van Laecke S, Malfait T, Schepers E, Van Biesen W.

Transpl Int. 2018 Jul;31(7):689-699. doi: 10.1111/tri.13160. Epub 2018 Apr 30. Review.

7.

Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate.

Gil RB, Ortiz A, Sanchez-Niño MD, Markoska K, Schepers E, Vanholder R, Glorieux G, Schmitt-Kopplin P, Heinzmann SS.

Nephrol Dial Transplant. 2018 Dec 1;33(12):2156-2164. doi: 10.1093/ndt/gfy020.

PMID:
29554320
8.

Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Vanholder R, Pletinck A, Schepers E, Glorieux G.

Toxins (Basel). 2018 Jan 8;10(1). pii: E33. doi: 10.3390/toxins10010033. Review.

9.

Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up.

Schepers E, Glorieux G, Eloot S, Hulko M, Boschetti-de-Fierro A, Beck W, Krause B, Van Biesen W.

BMC Nephrol. 2018 Jan 5;19(1):1. doi: 10.1186/s12882-017-0808-y.

10.

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.

Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zürbig P, Thijs L, Ramírez-Torres A, Heerspink HJL, Lindhardt M, Klein R, Orchard T, Porta M, Bilous RW, Charturvedi N, Rossing P, Vlahou A, Schepers E, Glorieux G, Mullen W, Delles C, Verhamme P, Vanholder R, Staessen JA, Mischak H, Jankowski J.

Kidney Int Rep. 2017 Nov;2(6):1066-1075. doi: 10.1016/j.ekir.2017.06.004.

11.

Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients.

Eloot S, Van Biesen W, Roels S, Delrue W, Schepers E, Dhondt A, Vanholder R, Glorieux G.

PLoS One. 2017 Oct 10;12(10):e0186010. doi: 10.1371/journal.pone.0186010. eCollection 2017.

12.

Binding of bromocresol green and bromocresol purple to albumin in hemodialysis patients.

Delanghe S, Biesen WV, Velde NV, Eloot S, Pletinck A, Schepers E, Glorieux G, Delanghe JR, Speeckaert MM.

Clin Chem Lab Med. 2018 Feb 23;56(3):436-440. doi: 10.1515/cclm-2017-0444.

PMID:
28985181
13.

The Place of Large Pore Membranes in the Treatment Portfolio of Patients on Hemodialysis.

Van Biesen W, Vanholder R, Schepers E, Glorieux G, Dhondt A, Eloot S.

Contrib Nephrol. 2017;191:168-177. doi: 10.1159/000479265. Epub 2017 Sep 14. Review.

PMID:
28910800
14.

Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Palisoul ML, Quinn JM, Schepers E, Hagemann IS, Guo L, Reger K, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2017 Dec;16(12):2881-2891. doi: 10.1158/1535-7163.MCT-17-0587. Epub 2017 Sep 13.

15.

Quantification of carbamylated albumin in serum based on capillary electrophoresis.

Delanghe S, Moerman A, Pletinck A, Schepers E, Glorieux G, Van Biesen W, Delanghe JR, Speeckaert MM.

Electrophoresis. 2017 Sep;38(17):2135-2140. doi: 10.1002/elps.201700068. Epub 2017 Jun 30.

PMID:
28556931
16.

Hereditary polycystic kidney disease is characterized by lymphopenia across all stages of kidney dysfunction: an observational study.

Van Laecke S, Kerre T, Nagler EV, Maes B, Caluwe R, Schepers E, Glorieux G, Van Biesen W, Verbeke F.

Nephrol Dial Transplant. 2018 Mar 1;33(3):489-496. doi: 10.1093/ndt/gfx040.

PMID:
28387829
17.

Foley catheter for induction of labour filled with 30mL or 60mL: A randomized controlled trial.

Sandberg EM, Schepers EM, Sitter RLV, Huisman CMA, Wijngaarden WJV.

Eur J Obstet Gynecol Reprod Biol. 2017 Apr;211:150-155. doi: 10.1016/j.ejogrb.2017.02.019. Epub 2017 Feb 24.

PMID:
28260689
18.

Understanding external cervical resorption patterns in endodontically treated teeth.

Mavridou AM, Hauben E, Wevers M, Schepers E, Bergmans L, Lambrechts P.

Int Endod J. 2017 Dec;50(12):1116-1133. doi: 10.1111/iej.12744. Epub 2017 Feb 27.

PMID:
28097666
19.

Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: a pilot study.

Boelaert J, Lynen F, Glorieux G, Schepers E, Neirynck N, Vanholder R.

Anal Bioanal Chem. 2017 Mar;409(8):2201-2211. doi: 10.1007/s00216-016-0165-x. Epub 2017 Jan 12.

PMID:
28083662
21.

Understanding External Cervical Resorption in Vital Teeth.

Mavridou AM, Hauben E, Wevers M, Schepers E, Bergmans L, Lambrechts P.

J Endod. 2016 Dec;42(12):1737-1751. doi: 10.1016/j.joen.2016.06.007. Epub 2016 Oct 21.

PMID:
27776885
22.

Cortical processes of speech illusions in the general population.

Schepers E, Bodar L, van Os J, Lousberg R.

BMC Neurosci. 2016 Oct 18;17(1):65.

23.

Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA.

Boelaert J, Schepers E, Glorieux G, Eloot S, Vanholder R, Lynen F.

Toxins (Basel). 2016 May 13;8(5). pii: E149. doi: 10.3390/toxins8050149.

24.

New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis.

Glorieux G, Mullen W, Duranton F, Filip S, Gayrard N, Husi H, Schepers E, Neirynck N, Schanstra JP, Jankowski J, Mischak H, Argilés À, Vanholder R, Vlahou A, Klein J.

Nephrol Dial Transplant. 2015 Nov;30(11):1842-52. doi: 10.1093/ndt/gfv254. Epub 2015 Jul 9.

PMID:
26160894
25.

Transcriptome analysis in patients with chronic kidney disease on hemodialysis disclosing a key role for CD16+CX3CR1+ monocytes.

Schepers E, Houthuys E, Dhondt A, De Meyer G, Neirynck N, Bernaert P, Van den Bergh R, Brouckaert P, Vanholder R, Glorieux G.

PLoS One. 2015 Apr 1;10(4):e0121750. doi: 10.1371/journal.pone.0121750. eCollection 2015.

26.

Soluble tumor necrosis factor receptor 1 and 2 predict outcomes in advanced chronic kidney disease: a prospective cohort study.

Neirynck N, Glorieux G, Schepers E, Verbeke F, Vanholder R.

PLoS One. 2015 Mar 30;10(3):e0122073. doi: 10.1371/journal.pone.0122073. eCollection 2015.

27.

A novel multimodular methodology to investigate external cervical tooth resorption.

Mavridou AM, Pyka G, Kerckhofs G, Wevers M, Bergmans L, Gunst V, Huybrechts B, Schepers E, Hauben E, Lambrechts P.

Int Endod J. 2016 Mar;49(3):287-300. doi: 10.1111/iej.12450. Epub 2015 Apr 16.

PMID:
25819599
28.

Hysterectomy in very obese and morbidly obese patients: a systematic review with cumulative analysis of comparative studies.

Blikkendaal MD, Schepers EM, van Zwet EW, Twijnstra AR, Jansen FW.

Arch Gynecol Obstet. 2015 Oct;292(4):723-38. doi: 10.1007/s00404-015-3680-7. Epub 2015 Mar 13. Review.

29.

Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to measure creatinine in human urine.

Fraselle S, De Cremer K, Coucke W, Glorieux G, Vanmassenhove J, Schepers E, Neirynck N, Van Overmeire I, Van Loco J, Van Biesen W, Vanholder R.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Apr 15;988:88-97. doi: 10.1016/j.jchromb.2015.02.026. Epub 2015 Feb 26.

PMID:
25756209
30.

Chronic kidney disease progression is mainly associated with non-recovery of acute kidney injury.

D'hoore E, Neirynck N, Schepers E, Vanholder R, Verbeke F, Van Thielen M, Van Biesen W.

J Nephrol. 2015 Dec;28(6):709-16. doi: 10.1007/s40620-015-0181-5. Epub 2015 Feb 21.

PMID:
25700932
31.

Pro-inflammatory cytokines and leukocyte oxidative burst in chronic kidney disease: culprits or innocent bystanders?

Neirynck N, Glorieux G, Schepers E, Dhondt A, Verbeke F, Vanholder R.

Nephrol Dial Transplant. 2015 Jun;30(6):943-51. doi: 10.1093/ndt/gfu409. Epub 2015 Jan 20.

PMID:
25609738
32.

The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.

Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G.

J Am Soc Nephrol. 2014 Sep;25(9):1897-907. doi: 10.1681/ASN.2013101062. Epub 2014 May 8. Review.

33.

Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?

Schepers E, Speer T, Bode-Böger SM, Fliser D, Kielstein JT.

Semin Nephrol. 2014 Mar;34(2):97-105. doi: 10.1016/j.semnephrol.2014.02.003. Epub 2014 Feb 17. Review.

PMID:
24780466
34.

Uremia-related oxidative stress in leukocytes is not triggered by β2-microglobulin.

Neirynck N, Glorieux G, Boelaert J, Schepers E, Liabeuf S, Dhondt A, Massy Z, Vanholder R.

J Ren Nutr. 2013 Nov;23(6):456-63. doi: 10.1053/j.jrn.2013.07.002. Epub 2013 Sep 7.

PMID:
24016624
35.

Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall.

Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Van Landschoot M, Eloot S, Rops A, Van de Voorde J, De Vriese A, van der Vlag J, Brunet P, Van Biesen W, Vanholder R.

J Am Soc Nephrol. 2013 Dec;24(12):1981-94. doi: 10.1681/ASN.2012030281. Epub 2013 Sep 5.

36.

Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins?

Liabeuf S, Glorieux G, Lenglet A, Diouf M, Schepers E, Desjardins L, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin (EUTox) Work Group.

PLoS One. 2013 Jun 24;8(6):e67168. doi: 10.1371/journal.pone.0067168. Print 2013.

37.

Review of protein-bound toxins, possibility for blood purification therapy.

Neirynck N, Glorieux G, Schepers E, Pletinck A, Dhondt A, Vanholder R.

Blood Purif. 2013;35 Suppl 1:45-50. doi: 10.1159/000346223. Epub 2013 Feb 25. Review.

PMID:
23466378
38.

Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration.

Mutsaers HA, Wilmer MJ, Reijnders D, Jansen J, van den Broek PH, Forkink M, Schepers E, Glorieux G, Vanholder R, van den Heuvel LP, Hoenderop JG, Masereeuw R.

Biochim Biophys Acta. 2013 Jan;1832(1):142-50. doi: 10.1016/j.bbadis.2012.09.006. Epub 2012 Sep 24.

39.

An update on uremic toxins.

Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G.

Int Urol Nephrol. 2013 Feb;45(1):139-50. doi: 10.1007/s11255-012-0258-1. Epub 2012 Aug 15. Review.

PMID:
22893494
40.

Ectopic bone formation by 3D porous calcium phosphate-Ti6Al4V hybrids produced by perfusion electrodeposition.

Chai YC, Kerckhofs G, Roberts SJ, Van Bael S, Schepers E, Vleugels J, Luyten FP, Schrooten J.

Biomaterials. 2012 Jun;33(16):4044-58. doi: 10.1016/j.biomaterials.2012.02.026. Epub 2012 Feb 28.

PMID:
22381474
41.

An update on protein-bound uremic retention solutes.

Vanholder R, Schepers E, Pletinck A, Neirynck N, Glorieux G.

J Ren Nutr. 2012 Jan;22(1):90-4. doi: 10.1053/j.jrn.2011.10.026. Review.

PMID:
22200422
42.

Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications.

Meert N, Schepers E, Glorieux G, Van Landschoot M, Goeman JL, Waterloos MA, Dhondt A, Van der Eycken J, Vanholder R.

Nephrol Dial Transplant. 2012 Jun;27(6):2388-96. doi: 10.1093/ndt/gfr672. Epub 2011 Dec 13.

PMID:
22167586
43.

an Obituary for GFR as the main marker for kidney function?

Vanholder R, Eloot S, Schepers E, Neirynck N, Glorieux G, Massy Z.

Semin Dial. 2012 Jan-Feb;25(1):9-14. doi: 10.1111/j.1525-139X.2011.01003.x. Epub 2011 Dec 6.

PMID:
22141430
44.

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Schepers E, Barreto DV, Liabeuf S, Glorieux G, Eloot S, Barreto FC, Massy Z, Vanholder R; European Uremic Toxin Work Group (EUTox).

Clin J Am Soc Nephrol. 2011 Oct;6(10):2374-83. doi: 10.2215/CJN.01720211. Epub 2011 Aug 4. Erratum in: Clin J Am Soc Nephrol. 2012 May;7(5):874.

45.

Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins.

Eloot S, Schepers E, Barreto DV, Barreto FC, Liabeuf S, Van Biesen W, Verbeke F, Glorieux G, Choukroun G, Massy Z, Vanholder R.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1266-73. doi: 10.2215/CJN.09981110. Epub 2011 May 26.

46.

Warning: the unfortunate end of p-cresol as a uraemic toxin.

Vanholder R, Bammens B, de Loor H, Glorieux G, Meijers B, Schepers E, Massy Z, Evenepoel P.

Nephrol Dial Transplant. 2011 May;26(5):1464-7. doi: 10.1093/ndt/gfr056. Epub 2011 Mar 15. No abstract available.

PMID:
21406546
47.

Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities.

Meert N, Eloot S, Schepers E, Lemke HD, Dhondt A, Glorieux G, Van Landschoot M, Waterloos MA, Vanholder R.

Nephrol Dial Transplant. 2011 Aug;26(8):2624-30. doi: 10.1093/ndt/gfq803. Epub 2011 Feb 10.

PMID:
21310741
48.

Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation.

Schepers E, Glorieux G, Dou L, Cerini C, Gayrard N, Louvet L, Maugard C, Preus P, Rodriguez-Ortiz M, Argiles A, Brunet P, Cohen G, Jankowski J, Jankowski V, Massy Z, Rodriguez M, Vanholder R; European Uremic Toxin Work Group (EUTox).

Blood Purif. 2010;30(4):277-87. doi: 10.1159/000320765. Epub 2010 Nov 16.

49.

Dinucleoside polyphosphates: newly detected uraemic compounds with an impact on leucocyte oxidative burst.

Schepers E, Glorieux G, Jankowski V, Dhondt A, Jankowski J, Vanholder R.

Nephrol Dial Transplant. 2010 Aug;25(8):2636-44. doi: 10.1093/ndt/gfq080. Epub 2010 Feb 26.

PMID:
20190246
50.

The gut: the forgotten organ in uremia?

Schepers E, Glorieux G, Vanholder R.

Blood Purif. 2010;29(2):130-6. doi: 10.1159/000245639. Epub 2010 Jan 8. Review.

PMID:
20093818

Supplemental Content

Loading ...
Support Center